Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02102802 · ClinicalTrials.gov registry record
Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD
A clinical trial, sponsored by Resilient Pharmaceuticals.
- Completed
- Registry status
- 10
- Enrollment target
NCT02102802: Completed study, sponsored by Resilient Pharmaceuticals.
NCT02102802 is a clinical trial that has completed, run by Resilient Pharmaceuticals. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02102802 has completed, sponsored by Resilient Pharmaceuticals.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
The goal of this observational sub-study is to provide information on how MDMA-assisted therapy affects the brain and body of people with chronic PTSD. The main question it aims to answer is: Is PTSD symptom reduction associated with changes in heart rate variability and brain activity? Participants from the MP-8 study will be invited to enroll in this sub-study where they will undergo an fMRI brain scan and other measurements of body function.
Interventions
- DRUG Midomafetamine
- BEHAVIORAL Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-08-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02102802
The ClinicalTrials.gov registry entry for NCT02102802 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Resilient Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Midomafetamine is the first listed.
NCT02102802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02102802 about?
NCT02102802 is a clinical study titled "Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD". The goal of this observational sub-study is to provide information on how MDMA-assisted therapy affects the brain and body of people with chronic PTSD. The main question it aims to answer is: Is PTSD symptom reduction associated with changes in heart rate variability and brain activity? Participan...
What is the current status of trial NCT02102802?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2014-01. Estimated completion is 2015-08-03.
What interventions are being tested in trial NCT02102802?
The interventions under investigation include: Midomafetamine (DRUG), Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT02102802?
This trial is sponsored by Resilient Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.